Epstein Secrets

From: To: Jeffrey Epstein Subject: Fwd: Fwd: Investment Opportunities-David Carter Date: Fri, 06 Mar 2015 15:42:07 +0000 Attachments: DaCart_Presentation Mar 2 2015.pptx

David Carter [madto: Sent: Thursday, March 05, 2015 11:09 AM To: ben carter Subject: Investment Opportunities Dear Lesley, Here is my email for Jeffery. Thanks, David Dear Jeffery, James Meiskin suggested you might have an interest in what I am doing. Since you offered to look at what I am up to,

From: To: Jeffrey Epstein Subject: Fwd: Fwd: Investment Opportunities-Dav

opment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to risk and retur

David Carter fmailto: Sent: Thursday, March 05, 2015 11:09 AM To: ben carter Subject: Investment Opportunities Dear Lesley, Here is my email for Jeffery. Thanks, David Dear Jeffery, James Meiskin suggested you might have an interest in what I am doing. Since you offered to look at what I am up to,

opment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. EFTA00351823 OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to

David Carter [mailto: Sent: Thursday, March 05, 2015 11:09 AM To: ben carter Subject: Investment Opportunities Dear Lesley, Here is my email for Jeffery. Thanks, David Dear Jeffery, James Meiskin suggested you might have an interest in what I am doing. Since you offered to look at what I am up to,

pment. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to risk and retur